Is the eGFR formula adequate for evaluating renal function before chemotherapy in patients with urogenital cancer? A suggestion for clinical application of eGFR formula
Background Accurate evaluation of renal function is required before cancer chemotherapy. Various kinds of formula have been developed for estimating creatinine clearance (Ccr) or glomerular filtration rate (GFR) conveniently. We retrospectively examined the reliability of the GFR estimating formula...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental nephrology 2015-08, Vol.19 (4), p.738-745 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 745 |
|---|---|
| container_issue | 4 |
| container_start_page | 738 |
| container_title | Clinical and experimental nephrology |
| container_volume | 19 |
| creator | Uozumi, Jiro Noguchi, Mitsuru Tokuda, Yuji Tobu, Shohei Udo, Kazuma Kakinoki, Hiroaki Kurata, Saya Nanri, Maki Ichibagase, Yuka Takahara, Kohei |
| description | Background
Accurate evaluation of renal function is required before cancer chemotherapy. Various kinds of formula have been developed for estimating creatinine clearance (Ccr) or glomerular filtration rate (GFR) conveniently. We retrospectively examined the reliability of the GFR estimating formula using the renal function data in cancer chemotherapy.
Methods
Clinical data of 12 patients with urogenital cancer from 1998 to 2013 in Saga University Hospital were reviewed. Patients were treated with 6–21 (median 10.5) courses of chemotherapy and those patients underwent 9–29 (median 14.5) times of 24hrCcr tests before and during chemotherapy. We compared estimated GFR (eGFR) with 24hrCcr. In addition, we developed a novel method to estimate the Ccr using the patient-inherent 24hrCcr/eGFR ratio, which is calculated from initial 3 or 4 determinations of 24hrCcr and the corresponding eGFR. Those estimated Ccrs were also compared with 24hrCcr.
Results
The dissociation between 24hrCcr and eGFR was not constant, and a large dissociation was observed in some cases. The newly devised estimated Ccr demonstrated less dissociation from 24hrCcr compared with eGFR.
Conclusions
The eGFR formula is not adequate for the clinical use in cancer chemotherapy. The absolute value of eGFR is not reliable, but clinical use of eGFR as relative value seems to be acceptable. To avoid troublesome 24hrCcr measurement in long-term cancer chemotherapy, eGFR formula can be used for estimating Ccr in combination with the specific inherent 24hrCcr/eGFR ratio, which is obtained from 3 or 4 times of actual 24hrCcr measurements. |
| doi_str_mv | 10.1007/s10157-014-1037-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1705643799</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3783670631</sourcerecordid><originalsourceid>FETCH-LOGICAL-c521t-3c0d718f1ddce64465e1afb26badf6df6197ba92ce2df8e1ec67dae98113b4633</originalsourceid><addsrcrecordid>eNp1kc9q3DAQxkVoyKZJHqCXIujZrcb_ZJ1KCE0aWAiE5CxkeeT14pW9kt2SN8pjZpxNS3sICDTSfPObkT7GPoH4CkLIbxEEFDIRkCcgMplkR-wUcgqkVOoDxVmeJiALWLGPMW6FEJUq1AlbpUVaLYRT9nwb-bRBjjfX99wNYTf3hpsG97OZcLng-Mv0dOh8ywN603M3ezt1g-c1Uh653eBuIEYw4xPvPB9JjH6K_Hc3bfgchhZ9N1GhNd5i-M4veZzbFuMrZGlh-853lhRmHHsKXhOD-2-oc3bsTB_x4m0_Y4_XPx6ufibru5vbq8t1YosUpiSzopFQOWgai2WelwWCcXVa1qZxJS1QsjYqtZg2rkJAW8rGoKoAsjovs-yMfTlwxzDsZxpSb4c50LujBimKkr5XKVLBQWXDEGNAp8fQ7Ux40iD08rP64I0mb_TijV7In9_Ic73D5m_FHzNIkB4EkVK-xfBP63epL24UnZ0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1705643799</pqid></control><display><type>article</type><title>Is the eGFR formula adequate for evaluating renal function before chemotherapy in patients with urogenital cancer? A suggestion for clinical application of eGFR formula</title><source>MEDLINE</source><source>SpringerLink (Online service)</source><creator>Uozumi, Jiro ; Noguchi, Mitsuru ; Tokuda, Yuji ; Tobu, Shohei ; Udo, Kazuma ; Kakinoki, Hiroaki ; Kurata, Saya ; Nanri, Maki ; Ichibagase, Yuka ; Takahara, Kohei</creator><creatorcontrib>Uozumi, Jiro ; Noguchi, Mitsuru ; Tokuda, Yuji ; Tobu, Shohei ; Udo, Kazuma ; Kakinoki, Hiroaki ; Kurata, Saya ; Nanri, Maki ; Ichibagase, Yuka ; Takahara, Kohei</creatorcontrib><description>Background
Accurate evaluation of renal function is required before cancer chemotherapy. Various kinds of formula have been developed for estimating creatinine clearance (Ccr) or glomerular filtration rate (GFR) conveniently. We retrospectively examined the reliability of the GFR estimating formula using the renal function data in cancer chemotherapy.
Methods
Clinical data of 12 patients with urogenital cancer from 1998 to 2013 in Saga University Hospital were reviewed. Patients were treated with 6–21 (median 10.5) courses of chemotherapy and those patients underwent 9–29 (median 14.5) times of 24hrCcr tests before and during chemotherapy. We compared estimated GFR (eGFR) with 24hrCcr. In addition, we developed a novel method to estimate the Ccr using the patient-inherent 24hrCcr/eGFR ratio, which is calculated from initial 3 or 4 determinations of 24hrCcr and the corresponding eGFR. Those estimated Ccrs were also compared with 24hrCcr.
Results
The dissociation between 24hrCcr and eGFR was not constant, and a large dissociation was observed in some cases. The newly devised estimated Ccr demonstrated less dissociation from 24hrCcr compared with eGFR.
Conclusions
The eGFR formula is not adequate for the clinical use in cancer chemotherapy. The absolute value of eGFR is not reliable, but clinical use of eGFR as relative value seems to be acceptable. To avoid troublesome 24hrCcr measurement in long-term cancer chemotherapy, eGFR formula can be used for estimating Ccr in combination with the specific inherent 24hrCcr/eGFR ratio, which is obtained from 3 or 4 times of actual 24hrCcr measurements.</description><identifier>ISSN: 1342-1751</identifier><identifier>EISSN: 1437-7799</identifier><identifier>DOI: 10.1007/s10157-014-1037-3</identifier><identifier>PMID: 25281007</identifier><identifier>CODEN: CENPFV</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Adult ; Aged ; Antineoplastic Agents - adverse effects ; Creatinine - blood ; Creatinine - urine ; Female ; Glomerular Filtration Rate ; Humans ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Nephrology ; Original Article ; Retrospective Studies ; Urogenital Neoplasms - drug therapy ; Urology ; Young Adult</subject><ispartof>Clinical and experimental nephrology, 2015-08, Vol.19 (4), p.738-745</ispartof><rights>Japanese Society of Nephrology 2014</rights><rights>Japanese Society of Nephrology 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c521t-3c0d718f1ddce64465e1afb26badf6df6197ba92ce2df8e1ec67dae98113b4633</citedby><cites>FETCH-LOGICAL-c521t-3c0d718f1ddce64465e1afb26badf6df6197ba92ce2df8e1ec67dae98113b4633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10157-014-1037-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10157-014-1037-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25281007$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Uozumi, Jiro</creatorcontrib><creatorcontrib>Noguchi, Mitsuru</creatorcontrib><creatorcontrib>Tokuda, Yuji</creatorcontrib><creatorcontrib>Tobu, Shohei</creatorcontrib><creatorcontrib>Udo, Kazuma</creatorcontrib><creatorcontrib>Kakinoki, Hiroaki</creatorcontrib><creatorcontrib>Kurata, Saya</creatorcontrib><creatorcontrib>Nanri, Maki</creatorcontrib><creatorcontrib>Ichibagase, Yuka</creatorcontrib><creatorcontrib>Takahara, Kohei</creatorcontrib><title>Is the eGFR formula adequate for evaluating renal function before chemotherapy in patients with urogenital cancer? A suggestion for clinical application of eGFR formula</title><title>Clinical and experimental nephrology</title><addtitle>Clin Exp Nephrol</addtitle><addtitle>Clin Exp Nephrol</addtitle><description>Background
Accurate evaluation of renal function is required before cancer chemotherapy. Various kinds of formula have been developed for estimating creatinine clearance (Ccr) or glomerular filtration rate (GFR) conveniently. We retrospectively examined the reliability of the GFR estimating formula using the renal function data in cancer chemotherapy.
Methods
Clinical data of 12 patients with urogenital cancer from 1998 to 2013 in Saga University Hospital were reviewed. Patients were treated with 6–21 (median 10.5) courses of chemotherapy and those patients underwent 9–29 (median 14.5) times of 24hrCcr tests before and during chemotherapy. We compared estimated GFR (eGFR) with 24hrCcr. In addition, we developed a novel method to estimate the Ccr using the patient-inherent 24hrCcr/eGFR ratio, which is calculated from initial 3 or 4 determinations of 24hrCcr and the corresponding eGFR. Those estimated Ccrs were also compared with 24hrCcr.
Results
The dissociation between 24hrCcr and eGFR was not constant, and a large dissociation was observed in some cases. The newly devised estimated Ccr demonstrated less dissociation from 24hrCcr compared with eGFR.
Conclusions
The eGFR formula is not adequate for the clinical use in cancer chemotherapy. The absolute value of eGFR is not reliable, but clinical use of eGFR as relative value seems to be acceptable. To avoid troublesome 24hrCcr measurement in long-term cancer chemotherapy, eGFR formula can be used for estimating Ccr in combination with the specific inherent 24hrCcr/eGFR ratio, which is obtained from 3 or 4 times of actual 24hrCcr measurements.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Creatinine - blood</subject><subject>Creatinine - urine</subject><subject>Female</subject><subject>Glomerular Filtration Rate</subject><subject>Humans</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Nephrology</subject><subject>Original Article</subject><subject>Retrospective Studies</subject><subject>Urogenital Neoplasms - drug therapy</subject><subject>Urology</subject><subject>Young Adult</subject><issn>1342-1751</issn><issn>1437-7799</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kc9q3DAQxkVoyKZJHqCXIujZrcb_ZJ1KCE0aWAiE5CxkeeT14pW9kt2SN8pjZpxNS3sICDTSfPObkT7GPoH4CkLIbxEEFDIRkCcgMplkR-wUcgqkVOoDxVmeJiALWLGPMW6FEJUq1AlbpUVaLYRT9nwb-bRBjjfX99wNYTf3hpsG97OZcLng-Mv0dOh8ywN603M3ezt1g-c1Uh653eBuIEYw4xPvPB9JjH6K_Hc3bfgchhZ9N1GhNd5i-M4veZzbFuMrZGlh-853lhRmHHsKXhOD-2-oc3bsTB_x4m0_Y4_XPx6ufibru5vbq8t1YosUpiSzopFQOWgai2WelwWCcXVa1qZxJS1QsjYqtZg2rkJAW8rGoKoAsjovs-yMfTlwxzDsZxpSb4c50LujBimKkr5XKVLBQWXDEGNAp8fQ7Ux40iD08rP64I0mb_TijV7In9_Ic73D5m_FHzNIkB4EkVK-xfBP63epL24UnZ0</recordid><startdate>20150801</startdate><enddate>20150801</enddate><creator>Uozumi, Jiro</creator><creator>Noguchi, Mitsuru</creator><creator>Tokuda, Yuji</creator><creator>Tobu, Shohei</creator><creator>Udo, Kazuma</creator><creator>Kakinoki, Hiroaki</creator><creator>Kurata, Saya</creator><creator>Nanri, Maki</creator><creator>Ichibagase, Yuka</creator><creator>Takahara, Kohei</creator><general>Springer Japan</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20150801</creationdate><title>Is the eGFR formula adequate for evaluating renal function before chemotherapy in patients with urogenital cancer? A suggestion for clinical application of eGFR formula</title><author>Uozumi, Jiro ; Noguchi, Mitsuru ; Tokuda, Yuji ; Tobu, Shohei ; Udo, Kazuma ; Kakinoki, Hiroaki ; Kurata, Saya ; Nanri, Maki ; Ichibagase, Yuka ; Takahara, Kohei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c521t-3c0d718f1ddce64465e1afb26badf6df6197ba92ce2df8e1ec67dae98113b4633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Creatinine - blood</topic><topic>Creatinine - urine</topic><topic>Female</topic><topic>Glomerular Filtration Rate</topic><topic>Humans</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Nephrology</topic><topic>Original Article</topic><topic>Retrospective Studies</topic><topic>Urogenital Neoplasms - drug therapy</topic><topic>Urology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Uozumi, Jiro</creatorcontrib><creatorcontrib>Noguchi, Mitsuru</creatorcontrib><creatorcontrib>Tokuda, Yuji</creatorcontrib><creatorcontrib>Tobu, Shohei</creatorcontrib><creatorcontrib>Udo, Kazuma</creatorcontrib><creatorcontrib>Kakinoki, Hiroaki</creatorcontrib><creatorcontrib>Kurata, Saya</creatorcontrib><creatorcontrib>Nanri, Maki</creatorcontrib><creatorcontrib>Ichibagase, Yuka</creatorcontrib><creatorcontrib>Takahara, Kohei</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Clinical and experimental nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Uozumi, Jiro</au><au>Noguchi, Mitsuru</au><au>Tokuda, Yuji</au><au>Tobu, Shohei</au><au>Udo, Kazuma</au><au>Kakinoki, Hiroaki</au><au>Kurata, Saya</au><au>Nanri, Maki</au><au>Ichibagase, Yuka</au><au>Takahara, Kohei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Is the eGFR formula adequate for evaluating renal function before chemotherapy in patients with urogenital cancer? A suggestion for clinical application of eGFR formula</atitle><jtitle>Clinical and experimental nephrology</jtitle><stitle>Clin Exp Nephrol</stitle><addtitle>Clin Exp Nephrol</addtitle><date>2015-08-01</date><risdate>2015</risdate><volume>19</volume><issue>4</issue><spage>738</spage><epage>745</epage><pages>738-745</pages><issn>1342-1751</issn><eissn>1437-7799</eissn><coden>CENPFV</coden><abstract>Background
Accurate evaluation of renal function is required before cancer chemotherapy. Various kinds of formula have been developed for estimating creatinine clearance (Ccr) or glomerular filtration rate (GFR) conveniently. We retrospectively examined the reliability of the GFR estimating formula using the renal function data in cancer chemotherapy.
Methods
Clinical data of 12 patients with urogenital cancer from 1998 to 2013 in Saga University Hospital were reviewed. Patients were treated with 6–21 (median 10.5) courses of chemotherapy and those patients underwent 9–29 (median 14.5) times of 24hrCcr tests before and during chemotherapy. We compared estimated GFR (eGFR) with 24hrCcr. In addition, we developed a novel method to estimate the Ccr using the patient-inherent 24hrCcr/eGFR ratio, which is calculated from initial 3 or 4 determinations of 24hrCcr and the corresponding eGFR. Those estimated Ccrs were also compared with 24hrCcr.
Results
The dissociation between 24hrCcr and eGFR was not constant, and a large dissociation was observed in some cases. The newly devised estimated Ccr demonstrated less dissociation from 24hrCcr compared with eGFR.
Conclusions
The eGFR formula is not adequate for the clinical use in cancer chemotherapy. The absolute value of eGFR is not reliable, but clinical use of eGFR as relative value seems to be acceptable. To avoid troublesome 24hrCcr measurement in long-term cancer chemotherapy, eGFR formula can be used for estimating Ccr in combination with the specific inherent 24hrCcr/eGFR ratio, which is obtained from 3 or 4 times of actual 24hrCcr measurements.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>25281007</pmid><doi>10.1007/s10157-014-1037-3</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1342-1751 |
| ispartof | Clinical and experimental nephrology, 2015-08, Vol.19 (4), p.738-745 |
| issn | 1342-1751 1437-7799 |
| language | eng |
| recordid | cdi_proquest_journals_1705643799 |
| source | MEDLINE; SpringerLink (Online service) |
| subjects | Adult Aged Antineoplastic Agents - adverse effects Creatinine - blood Creatinine - urine Female Glomerular Filtration Rate Humans Male Medicine Medicine & Public Health Middle Aged Nephrology Original Article Retrospective Studies Urogenital Neoplasms - drug therapy Urology Young Adult |
| title | Is the eGFR formula adequate for evaluating renal function before chemotherapy in patients with urogenital cancer? A suggestion for clinical application of eGFR formula |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T10%3A09%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Is%20the%20eGFR%20formula%20adequate%20for%20evaluating%20renal%20function%20before%20chemotherapy%20in%20patients%20with%20urogenital%20cancer?%20A%20suggestion%20for%20clinical%20application%20of%20eGFR%20formula&rft.jtitle=Clinical%20and%20experimental%20nephrology&rft.au=Uozumi,%20Jiro&rft.date=2015-08-01&rft.volume=19&rft.issue=4&rft.spage=738&rft.epage=745&rft.pages=738-745&rft.issn=1342-1751&rft.eissn=1437-7799&rft.coden=CENPFV&rft_id=info:doi/10.1007/s10157-014-1037-3&rft_dat=%3Cproquest_cross%3E3783670631%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1705643799&rft_id=info:pmid/25281007&rfr_iscdi=true |